JB Chemicals to acquire brands from Sanzyme for Rs 628 crore
JB Chemicals and Pharmaceuticals Ltd on Thursday said it will acquire brands for the Indian market from Sanzyme Pvt Ltd, a player in the probiotics and reproductive health segment, for Rs 628 crore. The brands to be acquired include those in the probiotics portfolio and reproductive health segment of Sanzyme, the company said in a statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 27, 2022 Category: Pharmaceuticals Source Type: news

Pharma industry wants Budget to announce incentives for conducting R & D
"An increase in the budgetary allocation from the current 1.8 per cent of the GDP to 2.5-3 per cent, as envisaged in the National Health Policy 2017 along with a separate allocation for the bio-pharmaceutical sector R&D is imperative," Organisation of Pharmaceutical Producers of India (OPPI) President S Sridhar told PTI. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 27, 2022 Category: Pharmaceuticals Source Type: news

Sun Pharma launches dry eye treatment product in Canada
The product is the first dry eye treatment available in Canada that is delivered with nanomicellar (NCELL) technology, which improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration, Sun Pharma said in a statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 27, 2022 Category: Pharmaceuticals Source Type: news

Biddano to expand reach in over 50 cities, GMV crosses $100 million
Biddano, a healthcare supply chain platform, said it will expand across India to over 52 cities by year-end, trebling its reach from 15 cities at present after pharmacy channels increasingly become organized and adopted online technology to address last-mile distribution issues. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 27, 2022 Category: Pharmaceuticals Source Type: news

Regular market approval granted for Covishield, Covaxin for use in adult population
Under the conditions, the firms shall submit data of ongoing clinical trials and the vaccines to be supplied for programmatic setting.Adverse event following immunisation will continue to be monitored. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 27, 2022 Category: Pharmaceuticals Source Type: news

Lupin partners with Exeltis for marketing its specialty drug Solosec in US
ET reported in October about Lupin trying to find a marketing partner or even be open to the idea of possible sale of its key specialty drug Solosec in the US. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 27, 2022 Category: Pharmaceuticals Source Type: news

Each dose of Covishield, Covaxin likely to be capped at Rs 275 after getting regular market approval
According to them, the National Pharmaceutical Pricing Authority (NPPA) has been directed to start working towards capping the price to make the vaccines affordable. As of now, Covaxin is priced at Rs 1,200 per dose while Covishield costs Rs 780 in private facilities. The prices include Rs 150 service charge. Both the vaccines are only authorised for emergency use in the country. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 26, 2022 Category: Pharmaceuticals Source Type: news

Immune response induced by Omicron effectively neutralise Delta variant: ICMR study
It suggests that the immune response induced by the Omicron could effectively neutralise the Delta variant, making the re-infection with Delta variant less likely, thereby displacing the Delta as dominant strain, the study said emphasising upon the need for Omicron-specific vaccine strategy. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 26, 2022 Category: Pharmaceuticals Source Type: news

New research hints at 4 factors that may increase chances of long COVID
Now, a team of researchers who followed more than 200 patients for two to three months after their COVID diagnoses report that they have identified biological factors that might help predict if a person will develop long COVID. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 26, 2022 Category: Pharmaceuticals Source Type: news

JBCPL to buy probiotic and reproductive brands from Sanzyme for Rs 628 crore
The acquired portfolio includes Sporlac which is the third largest probiotics brand in India and specialized products such as Lobun - a probiotic used for delaying progression of Chronic Kidney Disease and Oxalo - an alternate risk-free therapy to decalcify kidney stones. The reproductive health segment has a complete range of infertility and hormone products. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 26, 2022 Category: Pharmaceuticals Source Type: news

Coronavirus: Immunity due to Omicron variant can prevent Delta re-infection, says ICMR-NIV Study
(Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 26, 2022 Category: Pharmaceuticals Source Type: news

SEC no to clinical trial waiver for Pfizer's Covid pill
The SEC asked the companies to conduct bioavailability and bioequivalence (BA/BE) studies and submit safety data at its meeting on Friday, said people with knowledge of the matter. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 25, 2022 Category: Pharmaceuticals Source Type: news

Will an Omicron-specific vaccine help control COVID? There's one key problem
A vaccine targeting Omicron will increase immunity to the variant on both an individual and population level. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 25, 2022 Category: Pharmaceuticals Source Type: news

USFDA revokes emergency use status to two Covid antibody therapies
"Because data show these treatments are highly unlikely to be active against the omicron variant, which is circulating at a very high frequency throughout the United States, these treatments are not authorized for use in any U.S. states, territories, and jurisdictions at this time," USFDA said in a statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 25, 2022 Category: Pharmaceuticals Source Type: news

View: Blockchain could fix critical pain points in India's healthcare sector
The very nature of blockchain protects privacy and more importantly, gives patients control over their health records, making them both owner and custodian. Blockchain increases the security of data by storing data in decentralized locations, referred to as nodes, adding more layers of security. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 25, 2022 Category: Pharmaceuticals Source Type: news